The FDA has approved Cobenfy, the first new schizophrenia treatment in 30 years, offering a novel approach with fewer side effects. Developed by Karuna Therapeutics, the drug is set to provide new ...
Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...